SHP 656

Drug Profile

SHP 656

Alternative Names: BAX 826; Bax-826; Polysialylated rFVIII; PSA-FVIII - Shire/Xenetic Biosciences; PSA-rFVIII; SHP-826

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International; Xenetic Biosciences
  • Developer Shire; Xenetic Biosciences
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 18 Jul 2017 Discontinued - Phase-II for Haemophilia A in Spain, Russia, Poland, Netherlands, Italy, Hungary, Germany, Bulgaria and United Kingdom due to lack of efficacy (Parenteral)
  • 03 Apr 2017 Xenetic Biosciences plans a phase III trial for Haemophilia A
  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top